These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 18226004

  • 1. Tissue deposition of gadolinium and development of NSF: a convergence of factors.
    Perazella MA.
    Semin Dial; 2008; 21(2):150-4. PubMed ID: 18226004
    [Abstract] [Full Text] [Related]

  • 2. Patient characteristics and risk factors for nephrogenic systemic fibrosis following gadolinium exposure.
    Grobner T, Prischl FC.
    Semin Dial; 2008; 21(2):135-9. PubMed ID: 18226001
    [Abstract] [Full Text] [Related]

  • 3. [Nephrogenic systemic fibrosis].
    Breitschaft A, Stahlmann R.
    Med Monatsschr Pharm; 2009 Oct; 32(10):377-82. PubMed ID: 19886227
    [Abstract] [Full Text] [Related]

  • 4. Gadolinium-associated nephrogenic systemic fibrosis: the need for nephrologists' awareness.
    Canavese C, Mereu MC, Aime S, Lazzarich E, Fenoglio R, Quaglia M, Stratta P.
    J Nephrol; 2008 Oct; 21(3):324-36. PubMed ID: 18587720
    [Abstract] [Full Text] [Related]

  • 5. Nephrogenic systemic fibrosis risk: is there a difference between gadolinium-based contrast agents?
    Penfield JG, Reilly RF.
    Semin Dial; 2008 Oct; 21(2):129-34. PubMed ID: 18225999
    [Abstract] [Full Text] [Related]

  • 6. Current status of gadolinium toxicity in patients with kidney disease.
    Perazella MA.
    Clin J Am Soc Nephrol; 2009 Feb; 4(2):461-9. PubMed ID: 19201920
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Advanced kidney disease, gadolinium and nephrogenic systemic fibrosis: the perfect storm.
    Perazella MA.
    Curr Opin Nephrol Hypertens; 2009 Nov; 18(6):519-25. PubMed ID: 19623065
    [Abstract] [Full Text] [Related]

  • 9. Nephrogenic systemic fibrosis: more questions and some answers.
    Morcos SK, Thomsen HS.
    Nephron Clin Pract; 2008 Nov; 110(1):c24-31; discussion c32. PubMed ID: 18688172
    [Abstract] [Full Text] [Related]

  • 10. Possible role of gadolinium in nephrogenic systemic fibrosis: report of two cases and review of the literature.
    Lim YL, Lee HY, Low SC, Chan LP, Goh NS, Pang SM.
    Clin Exp Dermatol; 2007 Jul; 32(4):353-8. PubMed ID: 17433041
    [Abstract] [Full Text] [Related]

  • 11. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure.
    Deo A, Fogel M, Cowper SE.
    Clin J Am Soc Nephrol; 2007 Mar; 2(2):264-7. PubMed ID: 17699423
    [Abstract] [Full Text] [Related]

  • 12. Mechanism of NSF: New evidence challenging the prevailing theory.
    Newton BB, Jimenez SA.
    J Magn Reson Imaging; 2009 Dec; 30(6):1277-83. PubMed ID: 19937925
    [Abstract] [Full Text] [Related]

  • 13. [Nephrogenic systemic fibrosis and gadolinium-based contrast media].
    Andréjak M, Thuillier D, Lok C, Gras-Champel V.
    Therapie; 2007 Dec; 62(2):169-72. PubMed ID: 17582319
    [Abstract] [Full Text] [Related]

  • 14. Nephrogenic systemic fibrosis and gadolinium-based contrast: medico-legal implications.
    Houck CM, Pristave RJ, Kannensohn KJ.
    Semin Dial; 2008 Dec; 21(2):166-70. PubMed ID: 18226003
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review.
    Idée JM, Port M, Medina C, Lancelot E, Fayoux E, Ballet S, Corot C.
    Toxicology; 2008 Jun 27; 248(2-3):77-88. PubMed ID: 18440117
    [Abstract] [Full Text] [Related]

  • 17. Tissue distribution and kinetics of gadolinium and nephrogenic systemic fibrosis.
    Abraham JL, Thakral C.
    Eur J Radiol; 2008 May 27; 66(2):200-7. PubMed ID: 18374532
    [Abstract] [Full Text] [Related]

  • 18. Gadolinium use in patients with kidney disease: a cause for concern.
    Perazella MA, Rodby RA.
    Semin Dial; 2007 May 27; 20(3):179-85. PubMed ID: 17555477
    [Abstract] [Full Text] [Related]

  • 19. Can the risk of gadolinium be extrapolated to lanthanum?
    De Broe ME.
    Semin Dial; 2008 May 27; 21(2):142-4. PubMed ID: 18248522
    [Abstract] [Full Text] [Related]

  • 20. Gadodiamide contrast agent 'activates' fibroblasts: a possible cause of nephrogenic systemic fibrosis.
    Edward M, Quinn JA, Mukherjee S, Jensen MB, Jardine AG, Mark PB, Burden AD.
    J Pathol; 2008 Apr 27; 214(5):584-93. PubMed ID: 18220317
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.